✦ LIBER ✦

Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications

✍ Scribed by Stephen R. Marder; John W. Hubbard; Theodore Putten; Kamal K. Midha

Publisher: Springer
Year: 1989
Tongue: English
Weight: 937 KB
Volume: 98
Category: Article
ISSN: 0033-3158
DOI: 10.1007/bf00441937

No coin nor oath required. For personal study only.

✦ Synopsis

The authors review the literature regarding the pharmacokinetics of long-acting injectable neuroleptic drugs (LINS). There are important differences between LINS and oral neuroleptics that affect their pharmacokinetics. By avoiding first pass metabolism in gut and liver, LINS result in lower circulating concentrations of metabolites than are found after oral administration. In addition, LINS take more time to reach a stable steady state than their oral counterparts. The clinical significance of these pharmacokinetic properties is discussed. The authors recommend that when patients are being changed from oral neuroleptics to LINS, that this conversion be done gradually over several months.

📜 SIMILAR VOLUMES

Preparation and pharmacokinetic evaluati

Preparation and pharmacokinetic evaluation of a modified long-acting injectable norethisterone microsphere

✍ H. Cong; L. R. Beck 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 341 KB

Long-acting injectable risperidone and m

Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients

✍ Lucia Sara Volonteri; Giancarlo Cerveri; Ilaria Francesca De Gaspari; Maria Luis 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 173 KB

ChemInform Abstract: Genetic Polymorphis

ChemInform Abstract: Genetic Polymorphisms of SLCO1B1 for Drug Pharmacokinetics and Its Clinical Implications

✍ Hiroshi Takane 📂 Article 📅 2012 🏛 John Wiley and Sons ⚖ 18 KB

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4